Newsfeeds - Spark Newswire

1 minute read

DaVita Q3 EPS $2.36 Beats $2.25 Estimate, Sales $2.94B Beat $2.93B Estimate

Today, 10:01 PM

DaVita (NYSE:DVA) reported quarterly earnings of $2.36 per share which beat the analyst consensus estimate of $2.25 by 4.89 percent. This is a 31.11 percent increase over earnings of $1.80 per share from the same period

DVA

19 minute read

Earnings Scheduled For October 28, 2021

By Benzinga Insights

Today, 10:01 PM

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.

AAPL

1 minute read

Truist Securities Maintains Hold on DaVita, Lowers Price Target to $125

By Benzinga Newsdesk

Today, 10:01 PM

Truist Securities analyst David Macdonald maintains DaVita (NYSE:DVA) with a Hold and lowers the price target from $145 to $125.

DVA

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 10, 2021

By Benzinga Insights

Today, 10:01 PM

ACHC

2 minute read

A Peek Into The Markets: US Stock Futures Up Ahead Of Producer Price Index; Crude Oil Rises

By Lisa Levin

Today, 10:01 PM

Pre-open movers

AAPL

1 minute read

Cowen & Co. Initiates Coverage On DaVita with Market Perform Rating, Announces Price Target of $145

By Benzinga Newsdesk

Today, 10:01 PM

Cowen & Co. analyst Gary Taylor initiates coverage on DaVita (NYSE:DVA) with a Market Perform rating and announces Price Target of $145.

DVA

1 minute read

Earnings

Looking into DaVita’s Return on Capital Employed

By Benzinga Insights

Today, 10:01 PM

After pulling data from Benzinga Pro it seems like during Q2, DaVita (NYSE:DVA) earned $490.48 million, a 12.87% increase from the preceding quarter. DaVita also posted a total of $2.92 billion in sales, a 3.44% increase since Q1.

DVA

12 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 12, 2021

By Benzinga Insights

Today, 10:01 PM

ACHC

1 minute read

Barclays Downgrades DaVita to Equal-Weight, Raises Price Target to $146

By Benzinga Newsdesk

Today, 10:01 PM

Barclays analyst Sarah James downgrades DaVita (NYSE:DVA) from Overweight to Equal-Weight and raises the price target from $135 to $146.

DVA

3 minute read

News

Miromatrix Medical Reports Strategic Investors Were Involved In Series C Financing Following IPO: Baxter, CareDx, DaVita; No Size Of Investment Disclosed

By Benzinga Newsdesk

Today, 10:01 PM

Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save patients' lives and improve quality of life around the world,

BAX